Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Tarsus Pharmaceuticals Q1 2024 GAAP EPS $(1.01) Beats $(1.20) Estimate, Sales $27.614M Beat $17.460M Estimate

Author: Benzinga Newsdesk | May 08, 2024 04:33pm
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.20) by 15.83 percent. This is a 14.77 percent decrease over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $27.614 million which beat the analyst consensus estimate of $17.460 million by 58.16 percent. This is a 1.00K percent increase over sales of $2.500 million the same period last year.

Posted In: TARS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist